A Phase 3 interventional study of Efpeglenatide SAR439977 and Placebo in Type 2 Diabetes Mellitus, sponsored by Sanofi. Terminated at 47 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-02.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 186 studies in Diabetes Mellitus, Type 2 by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Sanofi.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 79th largest by enrollment of the 178 interventional ones that give a count, is one of 12 that started in 2018, is one of 80 in phase 3, and was the 165th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 186 studies in Diabetes Mellitus, Type 2 by Sanofi is open now, in 1 country. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
186 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 12 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 370 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 334 across the 178 interventional studies, 1,229 across the 5 observational. Of the 183 that completed or were terminated, 46 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately controlled with basal insulin alone or in combination with oral antidiabetic drugs (OADs).
Secondary Objectives:
Study duration per participant was approximately 64 weeks including an up to 2-week Screening Period, a 30-week Core Treatment Period, a 26-week Safety Extension Period, and a 6-week safety Follow-up Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Laboratory findings at the screening Visit:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo (matched to efpeglenatide) subcutaneous (SC) injection once weekly up to Week 56 on top of basal insulin alone or in combination with oral antidiabetic drugs (OADs).
Drug: Placebo · Drug: Background therapy
Participants received Efpeglenatide 2 milligrams (mg) SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs.
Drug: Efpeglenatide SAR439977 · Drug: Background therapy
Participants received Efpeglenatide 4 mg SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg and maintained at the 4 mg dose through-out the treatment duration up to Week 56.
Drug: Efpeglenatide SAR439977 · Drug: Background therapy
Participants received Efpeglenatide 6 mg SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg until Week 4 and later up-titrated to 6 mg and maintained at the 6 mg dose through-out the treatment duration up to Week 56.
Drug: Efpeglenatide SAR439977 · Drug: Background therapy
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Lantus (Insulin Glargine), SC, once daily; OADs, administered as per investigator prescription and in accordance with local labeling.
Change From Baseline to Week 30 in HbA1c
Time frame: Baseline to Week 30
Number of Participants With HbA1c <7.0% at Week 30
Participants who had no available assessment for HbA1c at Week 30 were considered as non-responders.
Time frame: Week 30
Change From Baseline to Week 56 in HbA1c
This analysis included Week 56 assessment performed per protocol as well as premature end of treatment/study visit recorded as Week 56 due to early termination.
Time frame: Baseline to Week 56
Change From Baseline to Week 30 in Fasting Plasma Glucose (FPG)
Time frame: Baseline to Week 30
Change From Baseline to Week 30 and Week 56 in Body Weight
This analysis included Week 56 assessment performed per protocol as well as premature end of treatment/study visit recorded as Week 56 due to early termination.
Time frame: Baseline to Week 30 and Week 56
Number of Participants With At Least One Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL], and Severe Hypoglycemia)
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<54 mg/dL (\<3.0 mmol/L). Severe hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.
Time frame: Baseline up to Week 56
Number of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<54 mg/dL (\<3.0 mmol/L). Severe hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.
Time frame: Baseline up to Week 56
The study was conducted at 47 active sites in 3 countries. A total of 540 participants were screened between 09 November 2018 and 02 September 2020, out of which 170 were screen failures. Screen failures were mainly due to inclusion criteria not met.
| Milestone | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Started | 92 | 92 | 93 | 93 |
| Safety population | 92 | 92 | 96 | 90 |
| Completed 30-week core treatment period | 50 | 52 | 51 | 49 |
| Completed | 6 | 5 | 5 | 6 |
| Not completed | 86 | 87 | 88 | 87 |
| Withdrew: Adverse event | 1 | 3 | 1 | 0 |
| Withdrew: Poor compliance to protocol | 2 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 14 | 6 | 14 | 16 |
| Withdrew: Other than specified | 69 | 77 | 73 | 70 |
| percentage of HbA1c | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Change From Baseline to Week 30 in HbA1c | -0.33 ± 1.09 | -1.27 ± 0.95 | -1.24 ± 0.96 | -1.43 ± 0.94 |
Participants who had no available assessment for HbA1c at Week 30 were considered as non-responders.
| Participants | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Number of Participants With HbA1c <7.0% at Week 30 | 10 | 32 | 28 | 40 |
This analysis included Week 56 assessment performed per protocol as well as premature end of treatment/study visit recorded as Week 56 due to early termination.
| percentage of HbA1c | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Change From Baseline to Week 56 in HbA1c | -0.32 ± 0.86 | -1.08 ± 0.77 | -1.23 ± 0.88 | -1.16 ± 1.34 |
| millimoles per liter (mmol/L) | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Change From Baseline to Week 30 in Fasting Plasma Glucose (FPG) | -0.41 ± 3.00 | -1.34 ± 2.80 | -1.33 ± 3.52 | -2.22 ± 1.89 |
This analysis included Week 56 assessment performed per protocol as well as premature end of treatment/study visit recorded as Week 56 due to early termination.
| kilograms | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Week 30 | 0.29 ± 3.23 | -0.68 ± 3.63 | -1.99 ± 3.13 | -3.14 ± 3.19 |
| Week 56 | 0.66 ± 3.22 | -2.39 ± 10.69 | -1.77 ± 5.36 | -2.85 ± 4.80 |
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<54 mg/dL (\<3.0 mmol/L). Severe hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.
| Participants | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Documented symptomatic hypoglycemia (<54 mg/dL) | 4 | 8 | 10 | 9 |
| Severe hypoglycemia | 1 | 2 | 1 | 2 |
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<54 mg/dL (\<3.0 mmol/L). Severe hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.
| events per participant-year | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| Documented symptomatic hypoglycemia (<54 mg/dL) | 0.07 | 0.27 | 0.45 | 0.46 |
| Severe hypoglycemia | 0.09 | 0.05 | 0.05 | 0.04 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent up to end of study (up to Week 62). Time frame for reporting of treatment emergent adverse events (TEAEs) was from first injection of Investigational Medicinal Product (IMP) up to 30 days after the last injection of the IMP (i.e. up to Week 60).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/92 (0%) | 9/92 (9.8%) | 25/92 (27.2%) |
| Efpeglenatide 2 mg | 0/92 (0%) | 7/92 (7.6%) | 33/92 (35.9%) |
| Efpeglenatide 4 mg | 0/96 (0%) | 5/96 (5.2%) | 42/96 (43.8%) |
| Efpeglenatide 6 mg | 0/90 (0%) | 10/90 (11.1%) | 46/90 (51.1%) |
| Event | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| SepsisInfections and infestations | 0/92 | 0/92 | 0/96 | 2/90 |
| Non-Cardiac Chest PainGeneral disorders | 0/92 | 1/92 | 0/96 | 2/90 |
| Covid-19 PneumoniaInfections and infestations | 0/92 | 0/92 | 2/96 | 0/90 |
| Squamous Cell Carcinoma Of LungNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/92 | 0/92 | 0/96 | 1/90 |
| SchizophreniaPsychiatric disorders | 0/92 | 0/92 | 0/96 | 1/90 |
| Hypoglycaemic UnconsciousnessNervous system disorders | 0/92 | 1/92 | 1/96 | 1/90 |
| CataractEye disorders | 0/92 | 0/92 | 0/96 | 1/90 |
| Atrial FibrillationCardiac disorders | 0/92 | 0/92 | 0/96 | 1/90 |
| Coronary Artery DiseaseCardiac disorders | 0/92 | 0/92 | 0/96 | 1/90 |
| Myocardial InfarctionCardiac disorders | 0/92 | 1/92 | 0/96 | 1/90 |
| Event | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 6/92 | 14/92 | 19/96 | 16/90 |
| DiarrhoeaGastrointestinal disorders | 7/92 | 10/92 | 15/96 | 14/90 |
| ConstipationGastrointestinal disorders | 3/92 | 5/92 | 5/96 | 14/90 |
| Decreased AppetiteMetabolism and nutrition disorders | 1/92 | 2/92 | 11/96 | 13/90 |
| VomitingGastrointestinal disorders | 4/92 | 4/92 | 12/96 | 9/90 |
| Gastrooesophageal Reflux DiseaseGastrointestinal disorders | 1/92 | 3/92 | 3/96 | 9/90 |
| Lipase IncreasedInvestigations | 2/92 | 9/92 | 4/96 | 8/90 |
| Amylase IncreasedInvestigations | 0/92 | 6/92 | 0/96 | 2/90 |
| Abdominal PainGastrointestinal disorders | 1/92 | 4/92 | 6/96 | 3/90 |
| Upper Respiratory Tract InfectionInfections and infestations | 5/92 | 4/92 | 4/96 | 5/90 |
Analysis was performed on Intent-to-treat (ITT) population which included all participants randomized irrespective of compliance with the study protocol and procedures analyzed, according to the treatment group allocated by randomization.
| Age, Continuous(years) | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg | Total |
|---|---|---|---|---|---|
| Mean | 58.9 ± 10.7 | 59.1 ± 10.7 | 60.6 ± 11.5 | 61.6 ± 10.3 | 60.1 ± 10.8 |
| Sex: Female, Male(Participants) | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg | Total |
|---|---|---|---|---|---|
| Female | 49 | 42 | 42 | 40 | 173 |
| Male | 43 | 50 | 51 | 53 | 197 |
| Race/Ethnicity, Customized(Participants) | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg | Total |
|---|---|---|---|---|---|
| White | 45 | 49 | 51 | 50 | 195 |
| Black or African American | 9 | 9 | 10 | 8 | 36 |
| Asian | 36 | 33 | 30 | 34 | 133 |
| Other | 2 | 1 | 1 | 1 | 5 |
| Unknown | 0 | 0 | 1 | 0 | 1 |
| Baseline Glycated Hemoglobin (HbA1c %)(percentage of HbA1c) | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg | Total |
|---|---|---|---|---|---|
| Mean | 8.54 ± 0.83 | 8.42 ± 0.79 | 8.46 ± 0.79 | 8.40 ± 0.72 | 8.46 ± 0.78 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | Placebo | Efpeglenatide 2 mg | Efpeglenatide 4 mg | Efpeglenatide 6 mg | Total |
|---|---|---|---|---|---|
| Mean | 30.1 ± 5.6 | 31.1 ± 6.1 | 30.0 ± 6.6 | 31.0 ± 7.1 | 30.6 ± 6.4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — No plan to share individual participant data (IPD) by SANOFI: Product rights transferred to Hanmi Pharmaceutical.
Ran from Nov 2018 to primary completion in Nov 2020, 24 months.
Results were first posted in Dec 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efpeglenatide